Pharmacogenomics
 | ADME PanelThe PharmaADME consortium (www.PharmaADME.org) created a consensus list of the known and likely functional variations present in key genes in absorption, distribution, metabolism, and excretion (ADME) of drugs. The most important ADME genes can be grouped into three main categories: Phase I and II metabolism enzymes, and transporters. The Core Marker list is the list of variants of the 34 genes that are considered to be most important. This assay set covers >95% of the Core Markers and consists of both TaqMan® DME and Copy Number Assays. |
Warfarin Metabolism
Common genetic variations in two genes, CYP2C9 and VKORC1, significantly impact an individual’s sensitivity to warfarin and dosage requirements. Warfarin is an anticoagulant drug commonly prescribed to aid prevention of thromboembolism and stroke. The correct dose of warfarin can be difficult to achieve, as various clinical and genetic factors can affect warfarin metabolism. Research is needed to better understand the association between the dosage and effect in various populations.
Common genetic variations in two genes, CYP2C9 and VKORC1, significantly impact an individual’s sensitivity to warfarin and dosage requirements. Warfarin is an anticoagulant drug commonly prescribed to aid prevention of thromboembolism and stroke. The correct dose of warfarin can be difficult to achieve, as various clinical and genetic factors can affect warfarin metabolism. Research is needed to better understand the association between the dosage and effect in various populations.
Drug Metabolism Genotyping
| Robust, reliable TaqMan®–based assays for over 175 ADME and CYP targets. |
|
